Sionna Therapeutics, Inc.(SION)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .

Sionna Therapeutics, Inc. (SION) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. SION is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Sionna Therapeutics, Inc. reports net income of $-29.9M, free cash flow of $-22.2M. Top institutional holders of SION by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., TPG GP A, VIKING GLOBAL INVESTORS, based on the most recent SEC filings. SION trades on the Nasdaq exchange and files with the SEC under CIK 2036042. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SION daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Sionna Therapeutics, Inc. directly from SEC EDGAR.

Net Income

$-29.9M

Free Cash Flow

$-22.2M

Institutions holding SION

Institutional investors reporting a position in Sionna Therapeutics, Inc. on SEC Form 13F.
InstitutionSharesValueReported
RA CAPITAL MANAGEMENT, L.P.9,905,045$435.7M2026-06-30
TPG GP A6,494,962$285.7M2026-06-30
VIKING GLOBAL INVESTORS3,195,181$140.6M2026-06-30
Atlas Venture Life Science Advisors2,995,602$131.8M2026-06-30
ORBIMED ADVISORS2,555,877$112.4M2026-06-30
Enavate Sciences GP2,478,030$109.0M2026-06-30
ADAGE CAPITAL PARTNERS GP, L.L.C.1,600,000$70.4M2026-06-30
BlackRock1,474,769$64.9M2026-06-30
JPMORGAN CHASE1,490,508$64.1M2026-06-30
JENNISON ASSOCIATES1,172,133$51.6M2026-06-30
SION

Sionna Therapeutics, Inc.

SION
NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Price Chart

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.
Reading the latest SEC filing… (first load can take ~20s)

Key Metrics

Net Income

Q2 2026
EDGAR

$-29.89M

EPS (Diluted)

Q2 2026
EDGAR

$-0.66

ROIC

Q2 2026
EDGAR

-48.9%

Free Cash Flow

Q2 2026
EDGAR

$-22.22M

Top Institutional Holders

as of Q2 2026
$2.12B total

Financial Trends

Revenue & Net Income

Earnings Per Share

Loading ratio trend…